Danazol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
The txgnn-pipeline skill covers model training and deployment — it doesn't apply to report generation. Proceeding directly with the evaluation report.
Danazol: From Endometriosis to Amenorrhea
One-Sentence Summary
Danazol is a synthetic androgen derivative approved by the U.S. FDA for endometriosis, fibrocystic breast disease, and hereditary angioedema. The TxGNN model predicts it may be effective for Amenorrhea, with 0 clinical trials and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Endometriosis, benign fibrocystic breast disease, hereditary angioedema (U.S. FDA-approved) |
| Predicted New Indication | Amenorrhea (disease) |
| TxGNN Prediction Score | 99.9999% |
| Evidence Level | L3 |
| Saudi Arabia Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the data source. Based on known information, danazol is a synthetic androgen derived from 17α-ethinyltestosterone. It suppresses pulsatile LH and FSH secretion from the hypothalamic-pituitary axis, directly inhibiting ovarian steroidogenesis and effectively inducing amenorrhea — a well-documented pharmacological consequence of standard therapeutic doses (400–800 mg/day).
The relationship between danazol's established indications and amenorrhea is mechanistically direct rather than merely associative. In endometriosis management, amenorrhea is simultaneously a side effect and the therapeutic mechanism: the hypoestrogenic, hypoprogestogenic state induced by danazol causes endometrial tissue regression. Likewise, in fibrocystic breast disease, danazol's suppression of cyclic hormonal fluctuations is central to relieving cyclical mastalgia and nodularity.
A 2024 retrospective multi-site cohort study (PMID 39051650) formally confirms danazol's utility as a deliberate menstrual suppressant in transgender and non-binary individuals — representing a recognized repurposing pathway where an established pharmacological side effect becomes a primary therapeutic goal. This shifts amenorrhea from an incidental finding to a codified clinical endpoint, strongly supporting the TxGNN model's prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39051650 | 2024 | Retrospective Cohort | Women's Health | Danazol effectively induces amenorrhea with reversible androgenic effects in transgender/non-binary individuals seeking menstrual suppression; confirms real-world efficacy as a primary endpoint |
| 2140996 | 1990 | RCT | Fertility and Sterility | Double-blind RCT (n=82) comparing nafarelin 400 µg/day vs danazol 600 mg/day in endometriosis over 6 months; both agents induced significant disease regression with amenorrhea as part of the treatment mechanism |
| 1533675 | 1992 | Review | J Royal Army Medical Corps | Survey-based review of therapeutic induction of amenorrhea; evaluates danazol alongside GnRH analogues, discussing efficacy, tolerability, and practical considerations including cost |
| 21701432 | 2011 | Review | Menopause | Evidence-based review of pharmacological therapies for abnormal uterine bleeding; positions danazol as a hormonal option with documented efficacy in reducing bleeding and inducing amenorrhea |
| 2404115 | 1990 | Review | J Reproductive Medicine | Comprehensive mechanistic review of danazol's biological effects; details central inhibition of gonadotropins, direct gonadal suppression, and immunoregulatory actions underpinning amenorrhea induction |
| 6819580 | 1982 | Article | Prog Clinical & Biological Research | Foundational paper on danazol in endometriosis; describes suppression of ovarian function and establishment of a hypoestrogenic amenorrheic state as the primary therapeutic mechanism |
| 16280355 | 2006 | Review | Human Reproduction Update | Endometriosis management update; explicitly notes that amenorrhea and menopause states promote lesion regression, contextualizing danazol's mechanism within the broader hormonal suppression paradigm |
| 2523321 | 1989 | Article | Fertility and Sterility | RCT comparing gestrinone vs danazol (n=39) in endometriosis; amenorrhea at 1 month used as a dose-adjustment criterion, underscoring its role as a measurable pharmacodynamic endpoint |
| 6210867 | 1982 | Article | Obstetrics and Gynecology | Double-blind dose-response study (100–600 mg/day, n=27); documents dose-dependent amenorrhea induction alongside endometriosis regression, establishing the dose-effect relationship |
| 2013670 | 1991 | Article | J Allergy and Clinical Immunology | 13-year long-term prophylaxis study in hereditary angioedema (n=56); danazol 200 mg/day effective at minimal doses; irregular menstruation documented as a dose-related hormonal effect |
Saudi Arabia Market Information
Danazol is currently not marketed in Saudi Arabia. No regulatory authorizations (SFDA) are on record.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Danazol's amenorrhea-inducing effect is a mechanistically direct, well-established pharmacological consequence of its gonadotropin-suppressing action, supported by one RCT, multiple observational studies, and a 2024 retrospective cohort study that formalizes amenorrhea as an intentional primary endpoint. Evidence is at L3 — robust enough to proceed, but without a dedicated Phase 2/3 RCT specifically targeting amenorrhea as the primary indication.
To proceed, the following is needed:
- Retrieve full mechanism of action data from DrugBank (DG002) and complete safety information from the package insert (DG001)
- Design a prospective clinical protocol with amenorrhea as a formal primary endpoint and prespecified patient populations (e.g., endometriosis-related dysmenorrhea, transgender menstrual suppression, premenstrual disorders)
- Establish a safety monitoring plan covering androgenic side effects (voice changes, hirsutism, acne), hepatotoxicity (liver function tests), and lipid profile changes — known class risks for attenuated androgens
- Initiate Saudi Arabia (SFDA) registration process, as danazol is currently not marketed; registration will be a prerequisite for any clinical use
- Evaluate whether lower doses (100–200 mg/day) can achieve adequate amenorrhea rates with an improved tolerability profile, given existing dose-response data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.